Verona Pharma
Acquired- Headquarters
- London
- Employees
- 51–200
- Business Model
- B2B
- Website
- veronapharma.com
About
Verona Pharma was a clinical-stage biopharmaceutical company headquartered in London, UK, with US offices in Raleigh, NC and Savannah, GA, focused on developing and commercializing novel treatments for chronic respiratory diseases including COPD, asthma, and cystic fibrosis. The company's lead product, Ohtuvayre (ensifentrine), became the first inhaled therapy for COPD maintenance treatment combining bronchodilator and non-steroidal anti-inflammatory activities in a single molecule. Verona Pharma was acquired by Merck in 2025 for approximately $10 billion.
Summary
Verona Pharma is a Biotech company based in London, United Kingdom. Investors include Oaktree Capital Management, RA Capital Management and OMERS Life Sciences.
Sign up to view the funding chart
Create a free account — 25 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
May 2024
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...